The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants

Author:

Ao Danyi1ORCID,He Xuemei1,Hong Weiqi1ORCID,Wei Xiawei1ORCID

Affiliation:

1. Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital, Sichuan University Chengdu Sichuan China

Abstract

AbstractAs the fifth variant of concern of the SARS‐CoV‐2 virus, the Omicron variant (B.1.1.529) has quickly become the dominant type among the previous circulating variants worldwide. During the Omicron wave, several subvariants have emerged, with some exhibiting greater infectivity and immune evasion, accounting for their fast spread across many countries. Recently, two Omicron subvariants, BQ.1 and XBB lineages, including BQ.1.1, XBB.1, and XBB.1.5, have become a global public health issue given their ability to escape from therapeutic monoclonal antibodies and herd immunity induced by prior coronavirus disease 2019 (COVID‐19) vaccines, boosters, and infection. In this respect, XBB.1.5, which has been established to harbor a rare mutation F486P, demonstrates superior transmissibility and immune escape ability compared to other subvariants and has emerged as the dominant strain in several countries. This review provides a comprehensive overview of the epidemiological features, spike mutations, and immune evasion of BQ.1 and XBB lineages. We expounded on the mechanisms underlying mutations and immune escape from neutralizing antibodies from vaccinated or convalescent COVID‐19 individuals and therapeutic monoclonal antibodies (mAbs) and proposed strategies for prevention against BQ.1 and XBB sublineages.

Publisher

Wiley

Subject

Cell Biology,Biochemistry (medical),Genetics (clinical),Computer Science Applications,Drug Discovery,Genetics,Oncology,Immunology and Allergy

Reference59 articles.

1. WHO.WHO Coronavirus (COVID‐19) Dashboard.2023. Accessed January 16 2023.https://covid19.who.int/

2. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB

3. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants

4. WHO.Tracking SARS‐CoV‐2 variants.2023. Accessed January 16 2023.https://www.who.int/activities/tracking‐SARS‐CoV‐2‐variants/tracking‐SARS‐CoV‐2‐variants

5. WHO.Statement on Omicron sublineages BQ.1 and XBB.2023. Accessed January 16 2023.https://www.who.int/news/item/27‐10‐2022‐tag‐ve‐statement‐on‐omicron‐sublineages‐bq.1‐and‐xbb

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3